Other Events ·
Clinuvel files NEURACTHEL Instant dossier with European regulators for ACTH treatment
CLVLFClinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Limited has submitted a marketing authorization dossier for its second pharmaceutical product, NEURACTHEL Instant (tetracosactide), to national European regulators under the European decentralised procedure. The filing targets initial approval in three key EU Member States based on commercial priorities and prescriber demand. If approved, Clinuvel will be able to commercialise the branded generic formulation as a prescription drug in those markets. The company expects first formal feedback from regulators in approximately four months following dossier validation. Clinuvel is a global biopharmaceutical company focused on developing and delivering innovative therapies for patients with genetic, metabolic, and dermatological disorders.